ARBUTUS BIOPHARMA CORP
NASDAQ: ABUS (Arbutus Biopharma Corporation)
Kemas kini terakhir: 3 jam lalu4.85
-0.03 (-0.61%)
| Penutupan Terdahulu | 4.88 |
| Jumlah Dagangan | 16,795,211 |
| Harga / Jualan (P/S) | 5.36 |
| Harga / Buku (P/B) | 3.83 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -738.49% |
| EPS Cair (TTM) | -0.410 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 15.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.07% |
| Nisbah Semasa (MRQ) | 6.01 |
| Aliran Tunai Operasi (OCF TTM) | -58.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.88 M |
| Pulangan Atas Aset (ROA TTM) | -31.58% |
| Pulangan Atas Ekuiti (ROE TTM) | -79.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Arbutus Biopharma Corporation | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.75 |
|
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 21.89% |
| % Dimiliki oleh Institusi | 59.38% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Two Seas Capital Lp | 30 Jun 2026 | 19,095,583 |
| Whitefort Capital Management, Lp | 30 Jun 2026 | 15,794,261 |
| Blackbarn Capital Partners Lp | 30 Jun 2026 | 2,500,000 |
| Woodline Partners Lp | 30 Jun 2026 | 2,281,856 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ANDROSKI LINDSAY | - | 5.01 | -82,527 | -413,460 |
| BEARDSLEY ROBERT A | - | 5.01 | -99,057 | -496,276 |
| NGUYEN TUAN | - | 5.01 | -206,637 | -1,035,251 |
| SAWHNEY ROGER | - | 5.01 | -100,508 | -503,545 |
| Jumlah Keseluruhan Kuantiti Bersih | -488,729 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,448,532 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 5.01 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BEARDSLEY ROBERT A | Pengarah | 18 Sep 2026 | Dibuang (-) | 99,057 | 5.01 | 496,276 |
| BEARDSLEY ROBERT A | Pengarah | 18 Sep 2026 | Pelaksanaan pilihan | 131,333 | - | - |
| SAWHNEY ROGER | Pengarah | 18 Sep 2026 | Dibuang (-) | 100,508 | 5.01 | 503,545 |
| SAWHNEY ROGER | Pengarah | 18 Sep 2026 | Pelaksanaan pilihan | 131,333 | - | - |
| NGUYEN TUAN | Pegawai | 18 Sep 2026 | Dibuang (-) | 206,637 | 5.01 | 1,035,251 |
| NGUYEN TUAN | Pegawai | 18 Sep 2026 | Pelaksanaan pilihan | 293,100 | - | - |
| ANDROSKI LINDSAY | Pegawai | 18 Sep 2026 | Dibuang (-) | 82,527 | 5.01 | 413,460 |
| ANDROSKI LINDSAY | Pegawai | 18 Sep 2026 | Pelaksanaan pilihan | 126,864 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |